Alzheimer's disease and type 2 diabetes via chronic inflammatory mechanisms

Saudi Journal of Biological Sciences

Volumn 22, Issue 1, 2015, Pages 4-13

  Mushtaq, Gohar ^a   Khan, Jalaluddin A ^a   Kumosani, Taha A ^a   Kamal, Mohammad A ^a  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Alzheimer's disease; Anti inflammatory drugs; C reactive protein; Cytokines; Hyperinsulinemia; Inflammation; Oxidative stress; Transgenic mouse models; Tumor necrosis factor ; Type 2 diabetes mellitus; Amyloid

Indexed keywords

MUS MUSCULUS;

EID: 84919838047     PISSN: 1319562X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sjbs.2014.05.003     Document Type: Review

References (105)

1. Aisen P.S., Schmeidler J., Pasinetti G.M. Randomized pilot study of nimesulide treatment in Alzheimer's disease. Neurology 2002, 58:1050-1054.
2. Akayama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., Cooper N.R., Eikelenboom P., Emmerling M., Fiebich B.L., Finch C.E., Frautschy S., Griffin W.S., Hampel H., Hull M., Landreth G., Lue L., Mrak R., Mackenzie I.R., McGeer P.L., O'Banion M.K., Pachter J., Pasinetti G., Plata-Salaman C., Rogers J., Rydel R., Shen Y., Streit W., Strohmeyer R., Tooyoma I., Van Muiswinkel F.L., Veerhuis R., Walker D., Webster S., Wegrzyniak B., Wenk G., Wyss-Coray T. Inflammation and Alzheimer's disease. Neurobiol. Aging 2000, 21:383-421.
3. Aliev G., Shahida K., Gan S.H., Firoz C.K., Khan A., Abuzenadah A., Kamal W., Kamal M.A., Tan Y., Qu X., Reale M. Alzheimer's disease and type 2 diabetes mellitus: the link to tyrosine hydroxylase and probable nutritional strategies. CNS Neurol. Disord. Drug Targets 2014, 13(3):467-477.
4. Al-Mallah M., Khawaja O., Sinno M., Alzohaili O., Samra A.B. Do angiotensin converting enzyme inhibitors or angiotensin receptor blockers prevent diabetes mellitus? A meta-analysis. Cardiol. J. 2010, 17(5):448-456.
5. Arvanitakis Z., Wilson R.S., Bienias J.L., Evans D.A., Bennett D.A. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch. Neurol. 2004, 61(5):661-666.
6. Blennow K., Wallin A., Fredman P., Karlsson I., Gottfries C.G., Svennerholm L. Blood-brain barrier disturbance in patients with Alzheimer's diseases related to vascular factors. Acta Neurol. Scand. 1990, 81(4):323-326.
7. Breteler M.M. Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol. Aging 2000, 21:153-160.
8. Bruunsgaard H., Pedersen B.K. Age-related inflammatory cytokines and disease. Immunol. Allergy Clin. North Am. 2003, 23:15-39.
9. Bruunsgaard H., Andersen-Ranberg K., Jeune B., Pedersen A.N., Skinhoj P., Pedersen B.K. A high plasma concentration of TNF-alpha is associated with dementia in centenarians. J. Gerontol. A Biol. Sci. Med. Sci. 1999, 54:M357-M364.
10. Buchanan T.A., Xiang A.H., Peters R.K., Kjos S.L., Marroquin A., Goico J., Ochoa C., Tan S., Berkowitz K., Hodis H.N., Azen S.P. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002, 51:2796-2803.
11. Centers for Disease Control and Prevention [CDC], 2006. Diabetes data and trends [online]. URL: http://www.cdc.gov/diabetes/statistics.
12. Chu N.V., Kong A.P., Kim D.D., Armstrong D., Baxi S., Deutsch R., Caulfield M., Mudaliar S.R., Reitz R., Henry R.R., Reaven P.D. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care 2002, 25:542-549.
13. Combs C.K., Johnson D.E., Karlo J.C., Cannady S.B., Landreth G.E. Inflammatory mechanisms in Alzheimer's disease: inhibition of β-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARg agonists. J. Neurosci. 2000, 20(2):558-567.
14. Cone J.B. Inflammation. Am. J. Surg. 2001, 182:558-562.
15. Dai Y., Kamal M.A. Fighting Alzheimer's disease and type 2 diabetes: pathological links and treatment strategies. CNS Neurol. Disord. Drug Targets 2014, 13(2):271-282.
16. de Oliveira, F.F., Bertolucci, P.H., Chen, E.S., Smith, M.C., 2014. Brain-penetrating angiotensin-converting enzyme inhibitors and cognitive change in patients with dementia due to Alzheimer's disease. J. Alzheimers Dis. http://www.ncbi.nlm.nih.gov/pubmed/24577465.
17. Deane R., Du Yan S., Submamaryan R.K., LaRue B., Jovanovic S., Hogg E., Welch D., Manness L., Lin C., Yu J., Zhu H., Ghiso J., Frangione B., Stern A., Schmidt A.M., Armstrong D.L., Arnold B., Liliensiek B., Nawroth P., Hofman F., Kindy M., Stern D., Zlokovic B. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med. 2003, 9:907-913.
18. Di Gregorio G.B., Yao-Borengasser A., Rasouli N., Varma V., Lu T., Miles L.M., Ranganathan G., Peterson C.A., McGehee R.E., Kern P.A. Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone. Diabetes 2005, 54:2305-2313.
19. Di Napoli M., Papa F. Angiotensin-converting enzyme inhibitor use is associated with reduced plasma concentration of C-reactive protein in patients with first-ever ischemic stroke. Stroke 2003, 34:2922-2929.
20. Diwan A., Khan S.A., Patel R., Krishna K., Firoz C.K., Kamal M.A. Spectrum from obesity to neurodegenerative disorder. Am. J. Neuroprotection Neuroregeneration 2012, 4(1):31-39.
21. Erol A. An integrated and unifying hypothesis for the metabolic basis of sporadic Alzheimer's disease. J. Alzheimers Dis. 2008, 13:241-253.
22. Evans J.L., Goldfine I.D., Maddux B.A., Grodsky G.M. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocrinol. Rev. 2002, 23(5):599-622.
23. Feinstein R., Kanety H., Papa M.Z., Lunenfeld B., Karasik A. Tumor necrosis factor-alpha suppresses insulin induced tyrosine phosphorylation of insulin receptor and its substrates. J. Biol. Chem. 1993, 268:26055-26058.
24. Ferre P. The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes 2004, 53(Suppl. 1):S43-S50.
25. Fillit H., Ding W.H., Buee L., Kalman J., Altstiel L., Lawlor B., Wolf-Klein G. Elevated circulating tumor necrosis factor levels in Alzheimer's disease. Neurosci. Lett. 1991, 129:318-320.
26. Fleischman A., Shoelson S.E., Bernier R., Goldfine A.B. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care 2008, 31(2):289-294.
27. Freeman D.J., Norrie J., Caslake M.J., Gaw A., Ford I., Lowe G.D., O'Reilly D.S., Packard C.J., Sattar N. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002, 51(5):1596-1600.
28. Furukawa S., Fujita T., Shimabukuro M., Iwaki M., Yamada Y., Nakajima Y., Nakayama O., Makishima M., Matsuda M., Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest. 2004, 114:1752-1761.
29. Gasparini L., Netzer W.J., Greengard P., Xu H. Does insulin dysfunction play a role in Alzheimer's disease?. Trends Pharmacol. Sci. 2002, 23:288-293.
30. Gengler S., McClean P., McCurtin R., Gault V., Holscher C. Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. Neurobiol. Aging 2012, 33(2):265-276.
31. Glenner G.G., Eanes E.D., Wiley C.A. Amyloid fibrils formed from a segment of the pancreatic islet amyloid protein. Biochem. Biophys. Res. Commun. 1988, 155:608-614.
32. Granic I., Dolga A.M., Nijholt I.M., van Dijk G., Eisel U.L. Inflammation and NF-kappaB in Alzheimer's disease and diabetes. J. Alzheimers Dis. 2009, 16(4):809-821.
33. Griffin W.S., Sheng J.G., Royston M.C., Gentleman S.M., McKenzie J.E., Graham D.I., Roberts G.W., Mrak R.E. Glial neuronal interactions in Alzheimer's disease: the potential role of a 'cytokine cycle' in disease progression. Brain Pathol. 1998, 8:65-72.
34. Gupta R., Gupta L.K. Improvement in long term and visuo-spatial memory following chronic pioglitazone in mouse model of Alzheimer's disease. Pharmacol. Biochem. Behav. 2012, 102(2):184-190.
35. Gurnell M. PPARgamma and metabolism: insights from the study of human genetic variants. Clin. Endocrinol. (Oxf.) 2003, 59(3):267-277.
36. Heneka M.T., Klockgether T., Feinstein D.L. Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J. Neurosci. 2000, 20(18):6862-6867.
37. Heneka M.T., Reyes-Irisarri E., Hüll M., Kummer M.P. Impact and therapeutic potential of PPARs in Alzheimer's disease. Curr. Neuropharmacol. 2011, 9(4):643-650.
38. Ho L., Qin W., Pompl P.N., Xiang Z., Wang J., Zhao Z., Peng Y., Cambareri G., Rocher A., Mobbs C.V., Hof P.R., Pasinetti G.M. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J. 2004, 18:902-904.
39. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993, 259:87-91.
40. Hunter K., Holscher C. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci. 2012, 13(1):33-38.
41. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat. Rev. Neurosci. 2004, 5(5):347-360.
42. In't Veld B.A., Ruitenberg A., Hofman A., Launer L.J., Van Duijin C.M., Stijnen T., Breteler M.M., Stricker B.H. Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer's disease. N. Engl. J. Med. 2001, 345:1515-1521.
43. Inflammation: a unifying theory of disease? Research is showing that chronic inflammation may be the common factor in many diseases, 2006. Harvard Health Letter, 31(6), pp. 4-5.
44. Iwai T., Ito S., Tanimitsu K., Udagawa S., Oka J. Glucagon-like peptide-1 inhibits LPS-induced IL-1beta production in cultured rat astrocytes. Neurosci. Res. 2006, 55:352-360.
45. Jabir N.R., Kamal M.A., Abuzenadah A.M., Gan S.H., Alama M.N., Baeesa S.S., Tabrez S. Alzheimer's and Type 2 diabetes management via common enzyme targeting. CNS Neurol. Disord. Drug Targets 2014, 13(2):299-304.
46. Johnson K.H., O'Brien T.D., Hayden D.W., Jordan K., Ghobrial H.K., Mahoney W.C., Westermark P. Immunolocalization of islet amyloid polypeptide (IAPP) in pancreatic beta cells by means of peroxidase-antiperoxidase (PAP) and protein A-gold techniques. Am. J. Pathol. 1988, 130:1-8.
47. Kaltschmidt B., Uherek M., Volk B., Baeuerle P.A., Kaltschmidt C. Transcription factor NF-kappaB is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proc. Natl. Acad. Sci. USA 1997, 94:2642-2647.
48. Kamal M.A., Tan Y., Seale J.P., Qu X. Targeting BuChE-inflammatory pathway by SK0506 to manage type 2 diabetes and Alzheimer disease. Neurochem. Res. 2009, 34(12):2163-2169.
49. Kamal, M.A., Bellante, V., Greig, N.H., 2011. Butyrylcholinesterase inhibitors modulate cytokines production in peripheral blood mononuclear cells. Alzheimers Dementia: J. Alzheimers Assoc. 7(Suppl. 4), 671-672.
50. Kamal M.A., Greig N.H., Priyamvada S., Arivarasu N.A., Jabir N.R., Tabrez S. Linking Alzheimer's disease and type 2 diabetes mellitus via aberrant insulin signaling and inflammation. CNS Neurol. Disord. Drug Targets 2014, 13(2):338-346.
51. Kastin A.J., Akerstrom V., Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J. Mol. Neurosci. 2002, 18:7-14.
52. Kiecolt-Glaser, J.K., Preacher, K.J., MacCallum, R.C., Atkinson, C., Malarkey, W.B., Glaser, R., 2003. Chronic stress and age-related increases in the proinflammatory cytokine IL-6. PNAS 100, 9090-9095.
53. Kitamura Y., Kakimura J., Matsuoka Y., Nomura Y., Gebicke-Haerter P.J., Taniguchi T. Activators of peroxisome proliferator-activated receptor-gamma (PPARgamma) inhibit inducible nitric oxide synthase expression but increase heme oxygenase-1 expression in rat glial cells. Neurosci. Lett. 1999, 262(2):129-132.
54. Kohjima M., Sun Y., Chan L. Increased food intake leads to obesity and insulin resistance in the Tg2576 Alzheimer's disease mouse model. Endocrinology 2010, 151(4):1532-1540.
55. Landreth G., Jiang Q., Mandrekar S., Heneka M. PPAR gamma agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics 2008, 5:481-489.
56. Lehrer, S., 2014. Nasal NSAIDs for Alzheimer's disease. Am. J. Alzheimers Dis. Other Demen. http://www.ncbi.nlm.nih.gov/pubmed/?term=24413537.
57. Leibson C.L., Rocca W.A., Hanson V.A., Cha R., Kokmen E., O'Brien P.C., Palumbo P.J. Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am. J. Epidemiol. 1997, 145:301-308.
58. Li Z.-G., Zhang W., Sima A.A. Alzheimer-like changes in rat models of spontaneous diabetes. Diabetes 2007, 56(7):1817-1824.
59. Lin Y., Berg A.H., Iyengar P., Lam T.K., Giacca A., Combs T.P., Rajala M.W., Du X., Rollman B., Li W., Hawkins M., Barzilai N., Rhodes C.J., Fantus I.G., Brownlee M., Scherer P.E. The hyperglycemia-induced inflammatory response in adipocytes: the role of reactive oxygen species. J. Biol. Chem. 2005, 280:4617-4626.
60. Liu L.P., Hong H., Liao J.M., Wang T.S., Wu J., Chen S.S., Li Y.Q., Long Y., Xia Y.Z. Upregulation of RAGE at the blood-brain barrier in streptozotocin induced diabetic mice. Synapse 2009, 63:636-642.
61. Liu F., Wang Y., Yan M., Zhang L., Pang T., Liao H. Glimepiride attenuates Aβ production via suppressing BACE1 activity in cortical neurons. Neurosci. Lett. 2013, 557(Pt. B):90-94.
62. Lovshin J.A., Drucker D.J. Incretin-based therapies for type 2 diabetes mellitus. Nat. Rev. Endocrinol. 2009, 5:262-269.
63. McClean P.L., Parthsarathy V., Faivre E., Hölscher C. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J. Neurosci. 2011, 31(17):6587-6594.
64. McGeer P.L., McGeer E.G. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res. Brain Res. Rev. 1995, 21:195-218.
65. Mohanty P., Aljada A., Ghanim H., Hofmeyer D., Tripathy D., Syed T., Al-Haddad W., Dhindsa S., Dandona P. Evidence for a potent antiinflammatory effect of rosiglitazone. J. Clin. Endocrinol. Metab. 2004, 89(6):2728-2735.
66. Moreno S., Farioli-Vecchioli S., Ceru M.P. Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience 2004, 123(1):131-145.
67. O'Neill L.A., Kaltschmidt C. NF-kappa B: a crucial transcription factor for glial and neuronal cell function. Trends Neurosci. 1997, 20:252-258.
68. Ott A., Stolk R.P., van H.F., Pols H.A., Hofman A., Breteler M.M. Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 1999, 53:1937-1942.
69. Peila R., Rodriguez B.L., Launer L.J. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes 2002, 51(4):1256-1262.
70. Peraldi P., Spiegelman B.M. Studies of the mechanism of inhibition of insulin signaling by tumor necrosis factor-alpha. J. Endocrinol. 1997, 155:219-220.
71. Perry T., Lahiri D.K., Sambamurti K., Chen D., Mattson M.P., Egan J.M., Greig N.H. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J. Neurosci. Res. 2003, 72:603-612.
72. Perry T., Holloway H.W., Weerasuriya A., Mouton P.R., Duffy K., Mattison J.A., Greig N.H. Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp. Neurol. 2007, 203:293-301.
73. Pradhan, A.D., Manson, J.E., Rifai, N., Buring, J.E., Ridker, P.M., 2001. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286, 327-334.
74. Priyadarshini M., Kamal M.A., Greig N.H., Reale M., Abuzenadah A.M., Chaudhary A.G., Damanhouri G.A. Alzheimer's disease and type 2 diabetes: exploring the association to obesity and tyrosine hydroxylase. CNS Neurol. Disord. Drug Targets 2012, 11(4):482-489.
75. Qiu C.X., Winblad B., Fratiglioni L. Risk factors for dementia and Alzheimer's disease - findings from a community-based cohort study in Stockholm, Sweden. Zhonghua Liu Xing Bing Xue Za Zhi 2005, 26:882-887.
76. Rasool M., Malik A., Qazi A., Sheikh I.A., Manan A., Shaheen S., Qazi M.H., Chaudhary A.G., Abuzenadah A.M., Asif M., Alqahtani M.H., Iqbal Z., Shaik M.M., Gan S.H., Kamal M.A. Current view from Alzheimer disease to type 2 diabetes mellitus. CNS Neurol. Disord. Drug Targets 2014, 13(3):533-542.
77. Reale M., Kamal M.A., Velluto L., Gambi D., Di Nicola M., Greig N.H. Relationship between inflammatory mediators, Aβ levels and APOE genotype in Alzheimer disease. Curr. Alzheimer Res 2011, 9(4):447-457.
78. Reale, M.A., Di Nicola, M., Velluto, L., D'Angelo, C., Costantini, E., Lahiri, D., Kamal, M.A., Yu, Q.S., Grei, N.H., 2013. Selective acetyl- and butyrylcholinesterase inhibitors reduce amyloid-b ex vivo activation of peripheral chemo-cytokines from Alzheimer's disease subjects: exploring the cholinergic anti-inflammatory pathway. Curr. Alzheimer Res. 11 http://www.ncbi.nlm.nih.gov/pubmed/24359497.
79. Risner M.E., Saunders A.M., Altman J.F., Ormandy G.C., Craft S., Foley I.M., Zvartau-Hind M.E., Hosford D.A., Roses A.D. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J. 2006, 6:246-254.
80. Rosenberg P.B. Clinical aspects of inflammation in Alzheimer's disease. Int. Rev. Psychiatry 2005, 17:503-514.
81. Sato T., Hanyu H., Hirao K., Kanetaka H., Sakurai H., Iwamoto T. Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease. Neurobiol. Aging 2009, 32(9):1626-1633.
82. Schmidt M.I., Duncan B.B., Sharrett A.R., Lindberg G., Savage P.J., Offenbacher S., Azambuja M.I., Tracy R.P., Heiss G. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 1999, 353:1649-1652.
83. Selkoe D.J. Clearing the brain's amyloid cobwebs. Neuron 2001, 32:177-180.
84. Seufert, J., Kieffer, T.J., Habener, J.F., 1999. Leptin inhibits insulin gene transcription and reverses hyperinsulinemia in leptin-deficient ob/ob mice. PNAS 96(2), 674-679.
85. Sheng J.G., Bora S.H., Xu G., Borchelt D.R., Price D.L., Koliatsos V.E. Lipopolysaccharide-induced-neuroinflammation increases intracellular accumulation of amyloid precursor protein and amyloid beta peptide in APPswe transgenic mice. Neurobiol. Dis. 2003, 14:133-145.
86. Soto M.E., van Kan G.A., Nourhashemi F., Gillette-Guyonnet S., Cesari M., Cantet C., Rolland Y., Vellas B. Angiotensin-converting enzyme inhibitors and Alzheimer's disease progression in older adults: results from the Réseau sur la Maladie d'Alzheimer Français cohort. J. Am. Geriatr. Soc. 2013, 61(9):1482-1488.
87. Steen E., Terry B.M., Rivera E.J., Cannon J.L., Neely T.R., Tavares R., Xu X.J., Wands J.R., de la Monte S.M. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes?. J. Alzheimers Dis. 2005, 7(1):63-80.
88. Strum J.C., Shehee R., Virley D., Richardson J., Mattie M., Selley P., Ghosh S., Nock C., Saunders A., Roses A. Rosiglitazone induces mitochondrial biogenesis in mouse brain. J. Alzheimers Dis. 2007, 11:45-51.
89. Sturchler-Pierrat C., Abramowski D., Duke M., Wiederhold K.H., Mistl C., Rothacher S., Ledermann B., Bürki K., Frey P., Paganetti P.A., Waridel C., Calhoun M.E., Jucker M., Probst A., Staufenbiel M., Sommer B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. USA 1997, 94:13287-13292.
90. Takeda S., Sato N., Uchio-Yamada K., Sawada K., Kunieda T., Takeuchi D., Kurinami H., Shinohara M., Rakugi H., Morishita R. Diabetes accelerated memory dysfunction via cerebrovascular inflammation and Aβ deposition in Alzheimer mouse model with diabetes. Proc. Natl. Acad. Sci. USA 2010, 107:7036-7041.
91. Takeda S., Sato N., Rakugi H., Morishita R. Molecular mechanisms linking diabetes mellitus and Alzheimer disease: beta-amyloid peptide, insulin signaling, and neuronal function. Mol. Biosyst. 2011, 7(6):1822-1827.
92. Terai K., Matsuo A., McGeer P.L. Enhancement of immunoreactivity for NF-kappa B in the hippocampal formation and cerebral cortex of Alzheimer's disease. Brain Res. 1996, 735:159-168.
93. Townsend M., Mehta T., Selkoe D.J. Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. J. Biol. Chem. 2007, 282:33305-33312.
94. Tschantz J.T., Corcoran C., Skoog I., Khachaturian A.S., Herrick J., Hayden K.M., Welsh-Bohmer K.A., Calvert T., Norton M.C., Zandi P., Breitner J.C. Dementia: the leading predictor of death in a defined elderly population: the Cache County study. Neurology 2004, 62:1156-1162.
95. Vozarova B., Weyer C., Lindsay R.S., Pratley R.E., Bogardus C., Tataranni P.A. High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002, 51:455-461.
96. Watson G.S., Peskind E.R., Asthana S., Purganan K., Wait C., Chapman D., Schwartz M.W., Plymate S., Craft S. Insulin increases CSF Abeta42 levels in normal older adults. Neurology 2003, 60(12):1899-1903.
97. Watson G.S., Cholerton B.A., Reger M.A., Baker L.D., Plymate S.R., Asthana S., Fishel M.A., Kulstad J.J., Green P.S., Cook D.G., Kahn S.E., Keeling M.L., Craft S. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am. J. Geriatr. Psychiatry 2005, 13(11):950-958.
98. Willson T.M., Lambert M.H., Kliewer S.A. Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu. Rev. Biochem. 2001, 70:341-367.
99. Wu J.D., Xu X.H., Zhu J., Ding B., Du T.X., Gao G., Mao X.M., Ye L., Lee K.O., Ma J.H. Effect of exenatide on inflammatory and oxidative stress markers in patients with type 2 diabetes mellitus. Diabetes Technol. Therapy 2011, 13:143-148.
100. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response?. Nat. Med. 2006, 12:1005-1015.
101. Xie, L., Helmerhorst, E., Taddei, K., Plewright, B., Van Bronswijk, W., Martins, R., 2002. Alzheimer's β-amyloid peptides compete for insulin binding to the insulin receptor. J. Neurosci. 22, RC221.
102. Yamamoto M., Kiyota T., Walsh S.M., Liu J., Kipnis J., Ikezu T. Cytokine-mediated inhibition of fibrillar amyloid beta peptide degradation by human mononuclear phagocytes. J. Immunol. 2008, 181:3877-3886.
103. Yasar S., Xia J., Yao W., Furberg C.D., Xue Q.L., Mercado C.I., Fitzpatrick A.L., Fried L.P., Kawas C.H., Sink K.M., Williamson J.D., DeKosky S.T., Carlson M.C. Antihypertensive drugs decrease risk of Alzheimer disease: ginkgo evaluation of memory study. Neurology 2013, 81(10):896-903.
104. Yasojima K., Schwab C., McGeer E.G., McGeer P.L. Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer's disease. Brain Res. 2000, 887:80-89.
105. Zandi P.P., Anthony J.C., Hayden K.M., Mehta K., Mayer L., Brietner J.C. Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County study. Neurology 2002, 59:880-886.